Sherene Loi

Summary

Affiliation: Peter MacCallum Cancer Centre
Country: Australia

Publications

  1. ncbi request reprint Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis
    Christos Sotiriou
    Functional Genomics and Translational Research Unit, Universite Libre de Bruxelles, Brussels, Belgium
    J Natl Cancer Inst 98:262-72. 2006
  2. pmc Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
    Sherene Loi
    Functional Genomics Unit, Jules Bordet Institute, Brussels, Belgium
    BMC Genomics 9:239. 2008
  3. pmc Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer
    Sherene Loi
    Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    J Natl Cancer Inst 105:960-7. 2013
  4. ncbi request reprint The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response
    Sherene Loi
    Translational Unit, Microarray Laboratories and Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    Crit Rev Oncol Hematol 61:187-94. 2007
  5. ncbi request reprint Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade
    Sherene Loi
    Jules Bordet Institute Machine Learning Group, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Oncol 25:1239-46. 2007
  6. ncbi request reprint Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer
    Marc Buyse
    International Drug Development Institute, Brussels, Belgium
    J Natl Cancer Inst 98:1183-92. 2006
  7. doi request reprint Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis
    Michail Ignatiadis
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Oncol 30:1996-2004. 2012
  8. doi request reprint Dissecting the heterogeneity of triple-negative breast cancer
    Otto Metzger-Filho
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Oncol 30:1879-87. 2012
  9. doi request reprint Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling
    Hatem A Azim
    Breast Cancer Translational Research Laboratory BCTL J C Heuson, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Clin Cancer Res 18:1341-51. 2012
  10. ncbi request reprint Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series
    Christine Desmedt
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Clin Cancer Res 13:3207-14. 2007

Detail Information

Publications27

  1. ncbi request reprint Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis
    Christos Sotiriou
    Functional Genomics and Translational Research Unit, Universite Libre de Bruxelles, Brussels, Belgium
    J Natl Cancer Inst 98:262-72. 2006
    ..We examined whether histologic grade was associated with gene expression profiles of breast cancers and whether such profiles could be used to improve histologic grading...
  2. pmc Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
    Sherene Loi
    Functional Genomics Unit, Jules Bordet Institute, Brussels, Belgium
    BMC Genomics 9:239. 2008
    ..Independent validation was performed using 362 tamoxifen-treated ER+ BC samples obtained from multiple institutions and treated with tamoxifen only in the adjuvant and metastatic settings...
  3. pmc Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer
    Sherene Loi
    Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    J Natl Cancer Inst 105:960-7. 2013
    ..This study investigated the frequencies, prognostic effects, and predictive effects of known cancer somatic mutations using a randomized, adjuvant, phase III clinical trial dataset...
  4. ncbi request reprint The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response
    Sherene Loi
    Translational Unit, Microarray Laboratories and Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    Crit Rev Oncol Hematol 61:187-94. 2007
    ....
  5. ncbi request reprint Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade
    Sherene Loi
    Jules Bordet Institute Machine Learning Group, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Oncol 25:1239-46. 2007
    ..However, although the basal and the ErbB2 subtypes are repeatedly recognized, identification of estrogen receptor (ER) -positive subtypes has been inconsistent. Therefore, refinement of their molecular definition is needed...
  6. ncbi request reprint Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer
    Marc Buyse
    International Drug Development Institute, Brussels, Belgium
    J Natl Cancer Inst 98:1183-92. 2006
    ..A 70-gene signature was previously shown to have prognostic value in patients with node-negative breast cancer. Our goal was to validate the signature in an independent group of patients...
  7. doi request reprint Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis
    Michail Ignatiadis
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Oncol 30:1996-2004. 2012
    ..To investigate the association between chemotherapy response and gene expression modules describing important biologic processes and druggable oncogenic pathways in breast cancer (BC) subtypes...
  8. doi request reprint Dissecting the heterogeneity of triple-negative breast cancer
    Otto Metzger-Filho
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Oncol 30:1879-87. 2012
    ....
  9. doi request reprint Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling
    Hatem A Azim
    Breast Cancer Translational Research Laboratory BCTL J C Heuson, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Clin Cancer Res 18:1341-51. 2012
    ..Breast cancer in young women is associated with poor prognosis. We aimed to define the role of gene expression signatures in predicting prognosis in young women and to understand biological differences according to age...
  10. ncbi request reprint Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series
    Christine Desmedt
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Clin Cancer Res 13:3207-14. 2007
    ..The aims of this study conducted by TRANSBIG were to independently validate these results and to compare the outcome with clinical risk assessment...
  11. pmc PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer
    Sherene Loi
    Breast Cancer Translational Research Laboratory, Jules Bordet Institute, Brussels, Belgium
    PLoS ONE 8:e53292. 2013
    ..Further evaluation of the PIK3CA-GS as a predictive biomarker is warranted as it may facilitate better selection of responsive patient populations for mTOR inhibition in combination with letrozole...
  12. doi request reprint Beyond trastuzumab: new treatment options for HER2-positive breast cancer
    Kamal S Saini
    Breast International Group, Brussels, Belgium
    Breast 20:S20-7. 2011
    ..Therefore, to avoid unnecessary toxicities and costs, it is critical to intensify the research for biomarkers that can identify those patients most likely to benefit from specific targeted therapies...
  13. doi request reprint Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98
    Sherene Loi
    Breast Cancer Translational Research Laboratory BCTL J C Heuson, Institut Jules Bordet, Blvd de Waterloo, 125, 1000 Brussels, Belgium
    J Clin Oncol 31:860-7. 2013
    ..We hypothesized that increased lymphocytic infiltration would be associated with good prognosis and benefit from immunogenic CT-in this case, anthracycline-only CT-in selected BC subtypes...
  14. doi request reprint Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer microenvironment
    Christine Desmedt
    Breast Cancer Translational Research Laboratory JC Heuson, Institut Jules Bordet, 125 Bld de Waterloo, Brussels 1000, Belgium
    Clin Cancer Res 18:1004-14. 2012
    ..Based on earlier research suggesting that during breast cancer progression, striking changes occur in CD10(+) stromal cells, we aimed to better characterize this cell population and its clinical relevance...
  15. doi request reprint A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints
    Debora Fumagalli
    Breast Cancer Translational Research Laboratory, Faculty of Medicine, Universite Libre de Bruxelles, Institut Jules Bordet, Brussels, Belgium
    Lancet Oncol 13:e240-8. 2012
    ..We expect that implementation of these recommendations will improve the conduct, reporting, and effectiveness of clinical trials and fully exploit the clinical and scientific potential of the neoadjuvant setting in breast cancer...
  16. ncbi request reprint Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial
    Jan Bogaerts
    Medical Oncology and Translational Research, Jules Bordet Institute, Boulevard de Waterloo 125, 1000 Brussels, Belgium
    Nat Clin Pract Oncol 3:540-51. 2006
    ..We hope that this article will trigger further discussion about the difficulties of setting up and analyzing trials aimed at establishing the worth of new methods for better selection of patients for cancer treatment...
  17. doi request reprint Gene profiling assay and application: the predictive role in primary therapy
    Debora Fumagalli
    Breast Cancer Translational Research Laboratory, Faculty of Medicine, Universite Libre de Bruxelles, Institut Jules Bordet, Bruxelles 1000, Belgium
    J Natl Cancer Inst Monogr 2011:124-7. 2011
    ....
  18. doi request reprint Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types
    Sherene Loi
    Breast International Group, and Breast Cancer Translational Research Laboratory, Institute Jules Bordet, Brussels, Belgium
    Lancet Oncol 12:1162-8. 2011
    ..If possible, patients should be referred at the outset to specialised centres to give them the opportunity to participate in neoadjuvant clinical trials, thereby avoiding several biopsy procedures...
  19. doi request reprint Clinical application of the 70-gene profile: the MINDACT trial
    Fatima Cardoso
    Jules Bordet Institute, Blvd de Waterloo, 125, 1000 Brussels, Belgium
    J Clin Oncol 26:729-35. 2008
    ..This article reviews the several steps in the development of the profile from its discovery to its clinical validation...
  20. ncbi request reprint Breast cancer gene expression profiling: clinical trial and practice implications
    Sherene Loi
    Jules Bordet Institute, Microarray Laboratories, Department of Medical Oncology, 121 Boulevard de Waterloo, Brussels 1000, Belgium
    Pharmacogenomics 6:49-58. 2005
    ..This will lead, ultimately, to the application of user-friendly tools derived from this technology to everyday patient care...
  21. doi request reprint Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer
    Kamal S Saini
    Breast International Group, Brussels, Belgium Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Cancer Treat Rev 39:935-46. 2013
    ..In this article, we present a review of the current relevant pre-clinical and clinical data and discuss the rationale for dual inhibition of these pathways in the treatment of BC patients. ..
  22. doi request reprint HER2-overexpressing breast cancer: time for the cure with less chemotherapy?
    Sherene Loi
    Breast Cancer Translational Research Laboratory, Institut Jules Bordet, l Université Libre de Bruxelles, Brussels, Belgium
    Curr Opin Oncol 23:547-58. 2011
    ..We review these findings and reflect on how they may influence the next generation of clinical trials in this breast cancer subtype...
  23. doi request reprint Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
    Dimitrios Zardavas
    BrEAST Data Center, Institut Jules Bordet, Brussels, Belgium
    Curr Opin Oncol 24:623-34. 2012
    ..We review these findings in the context of the preclinical data and the current status of biomarker development in this field...
  24. pmc Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection
    Carmen Criscitiello
    Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels
    Onco Targets Ther 4:1-11. 2011
    ..A combination of gene expression and genetic aberration markers may be most useful in discerning a population that is still appropriate for adjuvant tamoxifen treatment...
  25. ncbi request reprint Challenges in breast cancer clinical trial design in the postgenomic era
    Sherene Loi
    Translational Research Unit, Jules Bordet Institute, 121 Boulevard de Waterloo, Brussels 1000, Belgium
    Curr Opin Oncol 16:536-41. 2004
    ..The neoadjuvant setting presents a unique opportunity to test new concepts in a previously untreated patient population, because they may yield preliminary answers in a shorter time than that required in adjuvant trials...
  26. ncbi request reprint Obesity and outcomes in premenopausal and postmenopausal breast cancer
    Sherene Loi
    Peter MacCallum Cancer Centre, 723 Swanston Street, Carlton, Victoria 3053, Australia
    Cancer Epidemiol Biomarkers Prev 14:1686-91. 2005
    ..Obesity is associated with adverse outcomes in postmenopausal women with breast cancer. In premenopausal women, the association is less clear...
  27. ncbi request reprint Molecular forecasting of breast cancer: time to move forward with clinical testing
    Sherene Loi
    J Clin Oncol 24:721-2; author reply 722-3. 2006